Complement component C3 and butyrylcholinesterase activity are associated with neurodegeneration and clinical disability in multiple sclerosis

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Aeinehband, Shahin ^a   Lindblom, Rickard P F ^a   Nimer, Faiez Al ^a   Vijayaraghavan, Swetha ^a   Sandholm, Kerstin ^c   Khademi, Mohsen ^a   Olsson, Tomas ^a   Nilsson, Bo ^b   Ekdahl, Kristina Nilsson ^b,c   Darreh Shori, Taher ^a   Piehl, Fredrik ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c LINNAEUS UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE; COMPLEMENT COMPONENT C3; NEUROFILAMENT LIGHT PROTEIN; NEUROFILAMENT PROTEIN; UNCLASSIFIED DRUG; ACHE PROTEIN, HUMAN; BIOLOGICAL MARKER; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; IMMUNOLOGIC FACTOR; NEUROFILAMENT PROTEIN L;

ADULT; ARTICLE; BRAIN DAMAGE; CEREBROSPINAL FLUID ANALYSIS; CHOLINERGIC ACTIVITY; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DISABILITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN CEREBROSPINAL FLUID LEVEL; CASE CONTROL STUDY; CEREBROSPINAL FLUID; CRANIAL NERVE; CRANIAL NERVE INJURIES; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; PATHOLOGY; RECURRENT DISEASE; REMISSION; SEVERITY OF ILLNESS INDEX;

RATTUS;

ACETYLCHOLINESTERASE; ADULT; BIOMARKERS; BUTYRYLCHOLINESTERASE; CASE-CONTROL STUDIES; COMPLEMENT C3; CRANIAL NERVE INJURIES; CRANIAL NERVES; DISABILITY EVALUATION; FEMALE; GPI-LINKED PROTEINS; HUMANS; IMMUNOLOGIC FACTORS; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; NEUROFILAMENT PROTEINS; RECURRENCE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX;

EID: 84926652913     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0122048     Document Type: Article

References (61)

1. Compston A, Coles A. Multiple sclerosis. Lancet. 2008; 372(9648):1502-17. doi: 10.1016/S0140-6736 (08)61620-7 PMID: 18970977.
2. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006; 129(Pt 3):606-16. doi: 10.1093/brain/awl007 PMID: 16415308.
3. Tallantyre EC, Bo L, Al-Rawashdeh O, Owens T, Polman CH, Lowe JS, et al. Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis. Mult Scler. 2010; 16 (4):406-11. Epub 2010/03/11. doi: 10.1177/1352458510364992 PMID: 20215480.
4. Leray E, Yaouanq J, Le Page E, Coustans M, Laplaud D, Oger J, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain. 2010; 133(Pt 7):1900- 13. Epub 2010/04/29. doi: 10.1093/ brain/awq076 PMID: 20423930; PubMed Central PMCID: PMC2892936.
5. Weiner HL. A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. J Neurol. 2008; 255 Suppl 1:3-11. Epub 2008/04/09. doi: 10.1007/s00415-008-1002-8 PMID: 18317671.
6. Iacobaeus E, Amoudruz P, Strom M, Khademi M, Brundin L, Hillert J, et al. The expression of VEGF-A is down regulated in peripheral blood mononuclear cells of patients with secondary progressive multiple sclerosis. PloS one. 2011; 6(5):e19138. doi: 10.1371/journal.pone.0019138 PMID: 21573104; PubMed Central PMCID: PMC3089609.
7. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004; 14(2):164- 74. Epub 2004/06/15. PMID: 15193029.
8. Ingram G, Hakobyan S, Robertson NP, Morgan BP. Complement in multiple sclerosis: its role in disease and potential as a biomarker. Clin Exp Immunol. 2009; 155(2):128-39. Epub 2008/12/02. doi: 10. 1111/j.1365-2249.2008.03830.x PMID: 19040603; PubMed Central PMCID: PMC2675242.
9. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Annals of neurology. 2000; 47 (6):707-17. Epub 2000/06/14. PMID: 10852536.
10. Ingram G, Hakobyan S, Hirst CL, Harris CL, Pickersgill TP, Cossburn MD, et al. Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain. 2010; 133(Pt 6):1602-11. Epub 2010/04/28. doi: 10.1093/brain/awq085 PMID: 20421219.
11. Ingram G, Hakobyan S, Hirst C, Harris C, Loveless S, Mitchell J, et al. Systemic complement profiling in multiple sclerosis as a biomarker of disease state. Mult Scler. 2012. Epub 2012/02/23. doi: 10.1177/ 1352458512438238 PMID: 22354735.
12. Ingram G, Hakobyan S, Loveless S, Robertson N, Morgan BP. Complement Regulator Factor H in Multiple Sclerosis. J Cell Biochem. 2011; 112(10):2653-4. doi: 10.1002/Jcb.23204 PubMed PMID: ISI:000295623300001. PMID: 21618592
13. Teunissen CE, Koel-Simmelink MJ, Pham TV, Knol JC, Khalil M, Trentini A, et al. Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry. Mult Scler. 2011; 17 (7):838-50. doi: 10.1177/1352458511399614 PMID: 21505015.
14. Li Y, Qin Z, Yang M, Qin Y, Lin C, Liu S. Differential expression of complement proteins in cerebrospinal fluid from active multiple sclerosis patients. J Cell Biochem. 2011; 112(7):1930-7. Epub 2011/03/30. doi: 10.1002/jcb.23113 PMID: 21445879.
15. Teunissen CE, Koel-Simmelink MJ, Pham TV, Knol JC, Khalil M, Trentini A, et al. Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry. Mult Scler. 2011; 17 (7):838-50. Epub 2011/04/21. doi: 10.1177/1352458511399614 PMID: 21505015.
16. Stoop MP, Dekker LJ, Titulaer MK, Burgers PC, Sillevis Smitt PA, Luider TM, et al. Multiple sclerosis-related proteins identified in cerebrospinal fluid by advanced mass spectrometry. Proteomics. 2008; 8 (8):1576-85. doi: 10.1002/pmic.200700446 PMID: 18351689.
17. Wang Y, Hancock AM, Bradner J, Chung KA, Quinn JF, Peskind ER, et al. Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. The American journal of pathology. 2011; 178(4):1509-16. Epub 2011/03/26. doi: 10.1016/j.ajpath. 2011.01.006 PMID: 21435440; PubMed Central PMCID: PMC3078443.
18. Swanberg M, Duvefelt K, Diez M, Hillert J, Olsson T, Piehl F, et al. Genetically determined susceptibility to neurodegeneration is associated with expression of inflammatory genes. Neurobiol Dis. 2006; 24 (1):67-88. Epub 2006/08/29. doi: S0969-9961(06)00135-5 [pii] doi: 10.1016/j.nbd.2006.05.016 PMID: 16934480.
19. Lindblom RP, Strom M, Heinig M, Al Nimer F, Aeinehband S, Berg A, et al. Unbiased expression mapping identifies a link between the complement and cholinergic systems in the rat central nervous system. Journal of immunology. 2014; 192(3):1138-53. doi: 10.4049/jimmunol.1301233 PMID: 24353269.
20. Lehmann DJ, Johnston C, Smith AD. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. Hum Mol Genet. 1997; 6(11):1933-6. doi: 10.1093/hmg/6.11.1933 PubMed PMID: ISI:A1997YB59000021. PMID: 9302273
21. Darreh-Shori T, Vijayaraghavan S, Aeinehband S, Piehl F, Lindblom RP, Nilsson B, et al. Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer's disease. Neurobiol Aging. 2013. Epub 2013/06/14. doi: S0197-4580 (13)00195-4 [pii] doi: 10.1016/j.neurobiolaging.2013.04.027 PMID: 23759148.
22. Ruberg M, Villageois A, Bonnet AM, Pillon B, Rieger F, Agid Y. Acetylcholinesterase and butyrylcholinesterase activity in the cerebrospinal fluid of patients with neurodegenerative diseases involving cholinergic systems. J Neurol Neurosurg Psychiatry. 1987; 50(5):538-43. Epub 1987/05/01. PMID: 2953866; PubMed Central PMCID: PMC1031964.
23. Darvesh S, Leblanc AM, Macdonald IR, Reid GA, Bhan V, Macaulay RJ, et al. Butyrylcholinesterase activity in multiple sclerosis neuropathology. Chem Biol Interact. 2010; 187(1-3):425-31. Epub 2010/ 02/04. doi: S0009-2797(10)00061-X [pii] doi: 10.1016/j.cbi.2010.01.037 PMID: 20122907.
24. Kooi EJ, Prins M, Bajic N, Belien JA, Gerritsen WH, van Horssen J, et al. Cholinergic imbalance in the multiple sclerosis hippocampus. Acta Neuropathol. 2011; 122(3):313-22. Epub 2011/06/22. doi: 10. 1007/s00401-011-0849-4 PMID: 21691765; PubMed Central PMCID: PMC3168443.
25. Antonelli T, Tomasini MC, Castellazzi M, Sola P, Tamborino C, Ferraro D, et al. Biological markers in cerebrospinal fluid for axonal impairment in multiple sclerosis: acetylcholinesterase activity cannot be considered a useful biomarker. Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2013; 34(5):769-71. doi: 10.1007/s10072-012-1265-9 PMID: 23247598.
26. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001; 50(1):121-7. PMID: 11456302.
27. Henningsson AJ, Ernerudh J, Sandholm K, Carlsson SA, Granlund H, Jansson C, et al. Complement activation in Lyme neuroborreliosis-increased levels of C1q and C3a in cerebrospinal fluid indicate complement activation in the CNS. J Neuroimmunol. 2007; 183(1-2):200-7. doi: 10.1016/j.jneuroim. 2006.10.022 PMID: 17157926.
28. Darreh-Shori T, Brimijoin S, Kadir A, Almkvist O, Nordberg A. Differential CSF butyrylcholinesterase levels in Alzheimer's disease patients with the ApoE epsilon4 allele, in relation to cognitive function and cerebral glucose metabolism. Neurobiology of disease. 2006; 24(2):326-33. Epub 2006/09/16. doi: 10. 1016/j.nbd.2006.07.013 PMID: 16973370.
29. Darreh-Shori T, Kadir A, Almkvist O, Grut M, Wall A, Blomquist G, et al. Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine. Neurobiol Aging. 2008; 29(2):168-84. Epub 2007/01/02. doi: S0197-4580(06)00354-X [pii] doi: 10.1016/j. neurobiolaging.2006.09.020 PMID: 17196712.
30. International Multiple Sclerosis Genetics C, Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature genetics. 2013; 45(11):1353-60. doi: 10.1038/ng.2770 PMID: 24076602; PubMed Central PMCID: PMC3832895.
31. Teunissen CE, Dijkstra C, Polman C. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol. 2005; 4(1):32-41. Epub 2004/12/29. doi: 10.1016/S1474-4422(04) 00964-0 PMID: 15620855.
32. Gunnarsson M, Malmestrom C, Axelsson M, Sundstrom P, Dahle C, Vrethem M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Annals of neurology. 2011; 69 (1):83-9. Epub 2011/02/01. doi: 10.1002/ana.22247 PMID: 21280078.
33. Kuhle J, Plattner K, Bestwick JP, Lindberg RL, Ramagopalan SV, Norgren N, et al. A comparative study of CSF neurofilament light and heavy chain protein in MS. Mult Scler. 2013. Epub 2013/03/27. doi: 1352458513482374 [pii] doi: 10.1177/1352458513482374 PMID: 23529999.
34. Darreh-Shori T, Vijayaraghavan S, Aeinehband S, Piehl F, Lindblom RP, Nilsson B, et al. Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarkerprofiles in patients with Alzheimer's disease. Neurobiology of aging. 2013; 34(11):2465-81. doi: 10. 1016/j.neurobiolaging.2013.04.027 PMID: 23759148.
35. Darvesh S, Hopkins DA, Geula C. Neurobiology of butyrylcholinesterase. Nature reviews Neuroscience. 2003; 4(2):131-8. doi: 10.1038/nrn1035 PMID: 12563284.
36. Gunnarsson M, Malmestrom C, Axelsson M, Sundstrom P, Dahle C, Vrethem M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol. 2011; 69(1):83-9. Epub 2011/02/01. doi: 10.1002/ana.22247 PMID: 21280078.
37. Khademi M, Dring AM, Gilthorpe JD, Wuolikainen A, Al Nimer F, Harris RA, et al. Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers. PLoS One. 2013; 8(5):e63172. doi: 10.1371/journal.pone.0063172 PMID: 23667585; PubMed Central PMCID: PMC3646751.
38. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009; 132(Pt 5):1175-89. doi: 10.1093/brain/awp070 PMID: 19339255; PubMed Central PMCID: PMC2677799.
39. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nature reviews Neurology. 2012; 8(11):647-56. doi: 10.1038/nrneurol.2012.168 PMID: 23007702.
40. Axelsson M, Malmestrom C, Gunnarsson M, Zetterberg H, Sundstrom P, Lycke J, et al. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Mult Scler. 2013. Epub 2013/05/25. doi: 1352458513490544 [pii] doi: 10.1177/1352458513490544 PMID: 23702432.
41. Weiner HL. A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. Journal of neurology. 2008; 255 Suppl 1:3-11. doi: 10.1007/s00415-008-1002-8 PMID: 18317671.
42. Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol. 2009; 9 (10):729-40. Epub 2009/09/05. doi: nri2620 [pii] doi: 10.1038/nri2620 PMID: 19730437.
43. Ramaglia V, Hughes TR, Donev RM, Ruseva MM, Wu X, Huitinga I, et al. C3-dependent mechanism of microglial priming relevant to multiple sclerosis. Proc Natl Acad Sci U S A. 2012; 109(3):965-70. Epub 2012/01/06. doi: 1111924109 [pii] doi: 10.1073/pnas.1111924109 PMID: 22219359; PubMed Central PMCID: PMC3271873.
44. Chiu IM, Phatnani H, Kuligowski M, Tapia JC, Carrasco MA, Zhang M, et al. Activation of innate and humoral immunity in the peripheral nervous system of ALS transgenic mice. Proc Natl Acad Sci U S A. 2009; 106(49):20960-5. doi: 10.1073/pnas.0911405106 PMID: 19933335; PubMed Central PMCID: PMC2791631.
45. Fonseca MI, Ager RR, Chu SH, Yazan O, Sanderson SD, LaFerla FM, et al. Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J Immunol. 2009; 183(2):1375-83. doi: 10.4049/jimmunol.0901005 PMID: 19561098.
46. Sjoberg AP, Trouw LA, Blom AM. Complement activation and inhibition: a delicate balance. Trends in immunology. 2009; 30(2):83-90. doi: 10.1016/j.it.2008.11.003 PMID: 19144569.
47. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010; 11(9):785-97. Epub 2010/08/20. doi: ni.1923 [pii] doi: 10.1038/ ni.1923 PMID: 20720586; PubMed Central PMCID: PMC2924908.
48. Holton P, Ryten M, Nalls M, Trabzuni D, Weale ME, Hernandez D, et al. Initial assessment of the pathogenic mechanisms of the recently identified Alzheimer risk Loci. Ann Hum Genet. 2013; 77(2):85-105. Epub 2013/01/31. doi: 10.1111/ahg.12000 PMID: 23360175; PubMed Central PMCID: PMC3578142.
49. Rosas-Ballina M, Olofsson PS, Ochani M, Valdes-Ferrer SI, Levine YA, Reardon C, et al. Acetylcho-line-synthesizing T cells relay neural signals in a vagus nerve circuit. Science. 2011; 334(6052):98-101. Epub 2011/09/17. doi: 10.1126/science.1209985 PMID: 21921156.
50. Nizri E, Hamra-Amitay Y, Sicsic C, Lavon I, Brenner T. Anti-inflammatory properties of cholinergic upregulation: A new role for acetylcholinesterase inhibitors. Neuropharmacology. 2006; 50(5):540-7. Epub 2005/12/13. doi: S0028-3908(05)00383-7 [pii] doi: 10.1016/j.neuropharm.2005.10.013 PMID: 16336980.
51. De Simone R, Ajmone-Cat MA, Carnevale D, Minghetti L. Activation of alpha7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures. J Neuroinflammation. 2005; 2(1):4. doi: 10.1186/1742-2094-2-4 PMID: 15670336; PubMed Central PMCID: PMC548670.
52. van Gool WA, van de Beek D, Eikelenboom P. Systemic infection and delirium: when cytokines and acetylcholine collide. Lancet. 2010; 375(9716):773-5. doi: 10.1016/S0140-6736(09)61158-2 PMID: 20189029.
53. Shi FD, Piao WH, Kuo YP, Campagnolo DI, Vollmer TL, Lukas RJ. Nicotinic attenuation of central nervous system inflammation and autoimmunity. J Immunol. 2009; 182(3):1730-9. Epub 2009/01/22. doi: 182/3/1730 [pii]. PMID: 19155522.
54. Parada E, Egea J, Buendia I, Negredo P, Cunha AC, Cardoso S, et al. The Microglial alpha7-Acetylcholine Nicotinic Receptor Is a Key Element in Promoting Neuroprotection by Inducing Heme Oxygenase-1 via Nuclear Factor Erythroid-2-Related Factor 2. Antioxid Redox Signal. 2013. Epub 2013/01/15. doi: 10.1089/ars.2012.4671 PMID: 23311871.
55. Sifringer M, Bendix I, von Haefen C, Endesfelder S, Kalb A, Buhrer C, et al. Oxygen Toxicity Is Reduced by Acetylcholinesterase Inhibition in the Developing Rat Brain. Dev Neurosci. 2013. Epub 2013/03/01. doi: 000346723 [pii] doi: 10.1159/000346723 PMID: 23445753.
56. Krafft PR, Altay O, Rolland WB, Duris K, Lekic T, Tang J, et al. alpha7 nicotinic acetylcholine receptor agonism confers neuroprotection through GSK-3beta inhibition in a mouse model of intracerebral hemorrhage. Stroke. 2012; 43(3):844-50. doi: 10.1161/STROKEAHA.111.639989 PMID: 22207510; PubMed Central PMCID: PMC3293395.
57. Darvesh S, Kumar R, Roberts S, Walsh R, Martin E. Butyrylcholinesterase-Mediated enhancement of the enzymatic activity of trypsin. Cellular and molecular neurobiology. 2001; 21(3):285-96. PMID: 11569538.
58. Darvesh S, Grantham DL, Hopkins DA. Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation. The Journal of comparative neurology. 1998; 393(3):374-90. PMID: 9548556.
59. Malmsten L, Vijayaraghavan S, Hovatta O, Marutle A, Darreh-Shori T. Fibrillar beta-amyloid 1-42 alters cytokine secretion, cholinergic signalling and neuronal differentiation. Journal of cellular and molecular medicine. 2014; 18(9):1874-88. doi: 10.1111/jcmm.12343 PMID: 25109373; PubMed Central PMCID: PMC4196662.
60. Vijayaraghavan S, Karami A, Aeinehband S, Behbahani H, Grandien A, Nilsson B, et al. Regulated Extracellular Choline Acetyltransferase Activity- The Plausible Missing Link of the Distant Action of Acetylcholine in the Cholinergic Anti-Inflammatory Pathway. PloS one. 2013; 8(6):e65936. doi: 10.1371/ journal.pone.0065936 PMID: 23840379; PubMed Central PMCID: PMC3686815.
61. Malmsten L, Vijayaraghavan S, Hovatta O, Marutle A, Darreh-Shori T. Fibrillar beta-amyloid 1-42 alters cytokine secretion, cholinergic signalling and neuronal differentiation. J Cell Mol Med 2014 Aug 11 doi: 101111/jcmm12343. 2014. Epub 2014/08/12. doi: 10.1111/jcmm.12343 PMID: 25109373.